<DOC>
	<DOC>NCT01150890</DOC>
	<brief_summary>The study will examine the safety and effectiveness of AMG 827 for the treatment of moderate to severe Crohn's disease. Patients will randomly receive either AMG 827 or placebo (a lookalike liquid that doesn't have any drug in it) and neither the doctor nor the patient will know what treatment is being given.</brief_summary>
	<brief_title>AMG 827 in Subjects With Moderate to Severe Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Diagnosed with ileal, ileocolonic, or colonic Crohn's disease for a minimum of 6 months prior to initiating Study Product Moderately to severely active Crohn's disease, as defined by a CDAI score &gt;250 and &lt;450 at baseline Evidence of active inflammation Short bowel syndrome Stricture with obstructive symptoms within 3 months Bowel surgery within 3 months Ileostomy and/or colostomy Any gastric or intestinal pouch Ulcerative colitis Evidence of an infected abscess Bowel perforation or evidence of noninflammatory obstruction during the 6 months Stool positive for C. Difficile toxin at screening Presence of active infection requiring treatment Serious infection within 8 weeks Significant concurrent medical conditions Pregnant or breast feeding Significant Laboratory abnormalities Any antiTNF agent within 2 months Steroid enemas within 2 weeks Tysabri (natalizumab) within 1 year Biologic agents (eg, ustekinumab), experimental procedures, or live vaccines within 3 months Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin),thalidomide or tacrolimus within 2 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Ileal Crohn's Disease</keyword>
	<keyword>Ileo-colonic Crohn's Disease</keyword>
	<keyword>Colonic Chron's Disease</keyword>
</DOC>